Not Approved (US) Longevity & Mitochondrial

Visoluten

also known as: Retinal peptide bioregulator, Eye peptide preparation

The Khavinson retinal bioregulator preparation, marketed in Russia for age-related retinal change including macular degeneration support. Evidence base is Russian-language Khavinson-group studies. Not FDA- or EMA-approved.

A retinal-tissue-derived short peptide preparation in the Khavinson cytomedine series. Marketed in Russia for age-related retinal decline. Evidence for efficacy in age-related macular degeneration or diabetic retinopathy is limited to Russian-language studies from the Khavinson group and affiliated ophthalmology centers, with minimal methodological rigor by Western standards.

Mechanism of action

Proposed tissue-specific transcriptional modulation in retinal cells under the Khavinson bioregulator framework. Not mechanistically characterized at molecular-target resolution in peer-reviewed Western literature.

Primary uses

  • Age-related retinal aging support (Russian nutraceutical positioning)
  • Adjunct in age-related macular degeneration (Russian clinical positioning)
  • Adjunct in diabetic retinopathy (Russian clinical positioning)

Typical dosing

1–2 capsules 1–2 times daily in 20–30 day courses (oral)

Russian nutraceutical dosing. No controlled efficacy data.

Regulatory status

Not FDA- or EMA-approved. Russian nutraceutical status only.

References

  1. [review] Khavinson VK, et al. "Peptide bioregulators in geriatric ophthalmology." Vestn Oftalmol, 2008;124:55-58 (Russian).
  2. [review] Anisimov VN, Khavinson VK. "Peptide bioregulation of aging: results and prospects." Biogerontology, 2010;11:139-149.

Related peptides

Epithalon

A synthetic pineal tetrapeptide from the Khavinson group (St. Petersburg) — the only peptide with published data claiming telomerase activation and telomere elongation in human cell models.

Endoluten

The Khavinson pineal bioregulator preparation, positioned as a "precursor/complementary" product to epithalon (the synthetic AEDG tetrapeptide). Marketed in Russia for neuroendocrine and circadian support in aging. Evidence base is Russian-language Khavinson-group studies with minimal independent replication.

Cerluten

A Khavinson lung-derived short peptide bioregulator sold in Russia as a cytomedine supplement for respiratory aging. Like the rest of the Khavinson short-peptide family, supporting evidence is almost exclusively Russian-language and of low methodological rigor by Western standards; no independent replication, no FDA or EMA status, and no controlled clinical data.
Disclaimer

This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.